JoVE Logo
Faculty Resource Center

Sign In

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

DOI :

10.3791/57588-v

July 12th, 2018

July 12th, 2018

8,274 Views

1School of Pharmaceutical Sciences, Sun Yat-Sen University, 2Center for Cellular & Structural Biology, Sun Yat-Sen University

Here, we present a protocol to produce a bispecific antibody GPC3-S-Fab in Escherichia coli. The purified GPC3-S-Fab has potent cytotoxicity against GPC3 positive liver cancer cells.

-- Views

Related Videos

article

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors

article

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

article

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

article

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

article

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

article

Author Spotlight: High-Throughput Screening of CAR T-Cell Constructs for Enhanced Cytotoxicity and Immunologic Memory

article

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

article

Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor

article

Cytometer Assays of MPNST Cells Challenged with Therapeutic Agents

article

Human Omentum Specimen Processing and Co-Culture with Ovarian Cancer Cells

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved